Education
About Us
Working with TipRanks
Follow Us
Huakang Biomedical Holdings Company Limited (HK:8622)
:8622
8622 Stock Chart & Stats
HK$0.42
HK$0.01(7.32%)
At close: 4:00 PM EST
HK$0.42
HK$0.01(7.32%)
Day’s Range― - ―
52-Week RangeHK$0.13 - HK$0.75
Previous CloseN/A
Volume952.00K
Average Volume (3M)2.16M
Market Cap
HK$216.50M
Enterprise ValueN/A
Total Cash (Recent Filing)HK$36.73M
Total Debt (Recent Filing)HK$6.42M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding515,472,000
10 Day Avg. Volume2,620,800
30 Day Avg. Volume2,162,400
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.26
Price to Sales (P/S)2.68
P/FCF Ratio-13.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
8622 FAQ
What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?
Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.13 and its highest was HK$0.75 in the past 12 months.
What is Huakang Biomedical Holdings Company Limited’s market cap?
Huakang Biomedical Holdings Company Limited’s market cap is HK$216.50M.
When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?
Huakang Biomedical Holdings Company Limited’s upcoming earnings report date is Nov 18, 2025 which is 33 days ago.
How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?
Huakang Biomedical Holdings Company Limited released its earnings results on Aug 15, 2025. The company reported -HK$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.005.
Is Huakang Biomedical Holdings Company Limited overvalued?
According to Wall Street analysts Huakang Biomedical Holdings Company Limited’s price is currently Overvalued.
Does Huakang Biomedical Holdings Company Limited pay dividends?
Huakang Biomedical Holdings Company Limited does not currently pay dividends.
What is Huakang Biomedical Holdings Company Limited’s EPS estimate?
Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Huakang Biomedical Holdings Company Limited have?
Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding.
What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?
Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?
Currently, no hedge funds are holding shares in HK:8622
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Huakang Biomedical Holdings Company Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.50%
12-Months-Change
Fundamentals
Return on Equity
-8.71%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Huakang Biomedical Holdings Company Limited
Huakang Biomedical Holdings Company Limited (8622) is a biotechnology company focused on the research, development, and commercialization of innovative medical products and services. The company primarily operates in the healthcare sector, specializing in diagnostics and therapeutics that cater to various medical needs. Its core product offerings include advanced diagnostic kits, medical devices, and healthcare solutions aimed at enhancing patient outcomes and improving healthcare efficiency.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
China NT Pharma Group Co., Ltd.
―
Kontafarma China Holdings Ltd
―
PuraPharm Corp. Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―